Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial

AIM: In the EMPA‐REG OUTCOME trial, empagliflozin therapy reduced cardiovascular death by 38% compared with placebo when added to standard of care. Using the trial results, we created a discrete‐event simulation model to assess lifetime health economic outcomes in people with Type 2 diabetes and est...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansal, A., Reifsnider, O. S., Proskorovsky, I., Zheng, Y., Pfarr, E., George, J. T., Kandaswamy, P., Ruffolo, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851686/
https://www.ncbi.nlm.nih.gov/pubmed/31295358
http://dx.doi.org/10.1111/dme.14076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851686/
https://www.ncbi.nlm.nih.gov/pubmed/31295358
http://dx.doi.org/10.1111/dme.14076

Ejemplares similares